Affimed N.V. (AFMD)
Stock Price:
$3.47 USD
-0.38 (-9.87%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
264.59M |
| Revenue (ttm) |
24.03M |
| Net Income (ttm) |
-36.37M |
| Shares Out |
76.25M |
| EPS (ttm) |
-0.72 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$3.47 |
| Previous Close |
$3.85 |
| Change ($) |
-0.38 |
| Change (%) |
-9.87% |
| Day's Open |
3.80 |
| Day's Range |
3.23 - 3.94 |
| Day's Volume |
1,821,808 |
| 52-Week Range |
1.42 - 4.91 |
More Stats
| Market Cap |
264.59M |
| Enterprise Value |
151.16M |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
76.25M |
| Float |
60.77M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.72 |
| FCF / Share |
-0.54 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.89M |
| Short Ratio |
2.37 |
| Short % of Float |
6.66% |
| Beta |
2.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
11.01 |
| PB Ratio |
7.82 |
| Revenue |
24.03M |
| Operating Income |
-36.70M |
| Net Income |
-36.37M |
| Free Cash Flow |
-34.59M |
| Net Cash |
113.43M |
| Net Cash / Share |
1.48 |
| Gross Margin |
100.00% |
| Operating Margin |
-152.71% |
| Profit Margin |
-151.30% |
| FCF Margin |
-143.91% |
| ROA |
-26.17% |
| ROE |
-115.13% |
| ROIC |
251.10% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.36*
(112.23% upside)
Low
5.70
Current: $3.47
High
10.36
Target: 7.36
*Average 12-month USD price target from 5 stock analysts.
Financial Performance
Financial numbers in millions EUR.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 21.39 | 23.74 | 2.01 | 6.31 | 7.56 | 3.38 | 5.09 | 1.17 |
| Revenue Growth | -9.88% | 1080.85% | -68.17% | -16.5% | 123.6% | -33.52% | 333.67% | - |
| Gross Profit | 21.39 | 23.74 | 2.01 | 6.31 | 7.56 | 3.38 | 5.09 | 1.17 |
| Operating Income | -32.67 | -21.05 | -27.47 | -32.19 | -21.99 | -8.56 | -16.31 | -10.60 |
| Net Income | -32.37 | -19.48 | -30.22 | -32.22 | -20.24 | -0.26 | -26.10 | -14.31 |
| Shares Outstanding | 64.24 | 60.51 | 43.75 | 33.26 | 23.98 | 23.98 | - | - |
| Earnings Per Share | -0.50 | -0.32 | -0.69 | -0.97 | -0.71 | -0.01 | -1.76 | -0.97 |
| Operating Cash Flow | -29.46 | 49.56 | -25.31 | -31.65 | -17.99 | -10.35 | -5.67 | -8.65 |
| Capital Expenditures | -1.32 | -0.69 | -0.59 | -0.24 | -0.25 | -0.25 | -0.13 | -0.03 |
| Free Cash Flow | -30.78 | 48.87 | -25.90 | -31.89 | -18.24 | -10.60 | -5.81 | -8.68 |
| Cash & Equivalents | 104 | 109 | 39.84 | 44.89 | 76.74 | 39.73 | 4.15 | 0.00 |
| Total Debt | 3.19 | 4.77 | 7.17 | 4.59 | 4.58 | 3.90 | 4.80 | - |
| Net Cash / Debt | 101 | 104 | 32.67 | 40.30 | 72.16 | 35.83 | -0.65 | 0.00 |
| Assets | 112 | 116 | 43.16 | 48.74 | 79.32 | 41.91 | 6.50 | - |
| Liabilities | 73.69 | 76.05 | 11.58 | 9.99 | 12.05 | 10.11 | 106 | - |
| Book Value | 38.67 | 40.13 | 31.58 | 38.75 | 67.27 | 31.80 | -99.22 | - |
Numbers in millions EUR, except per-share numbers.
Company Details
| Full Name |
Affimed N.V. |
| Country |
Germany |
| Employees |
137 |
| CEO |
Adolf Hoess |
Stock Information
| Ticker Symbol |
AFMD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AFMD |
| IPO Date |
September 12, 2014 |
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.